Form 4: Omnicell CEO Randall Lipps Reports Stock Transactions Following Vesting of Performance-Based Restricted Stock Units

Omnicell's CEO, Randall Lipps, reports acquiring shares through vested performance-based restricted stock units and disposing of shares to cover tax obligations.

Summary

• Randall A. Lipps, CEO of Omnicell, filed a Form 4 detailing changes in beneficial ownership of company stock.
• On March 8, 2025, Mr. Lipps acquired 188,794 shares of common stock related to performance-based restricted stock units that vested due to the company meeting certain stock performance objectives compared to the S&P 1000 Healthcare Index.
• The Compensation Committee determined the performance criteria was met with respect to 188,794 performance-based restricted stock units (176% of target) of which 25% vested upon the determination date.
• He also disposed of 18,571 shares to cover taxes due in connection with the vesting of these restricted stock units at a price of $36.99 per share.
• Following these transactions, Mr. Lipps directly owns 323,049 shares and indirectly owns 355,861 shares in trust with his wife and 8,051 shares in trust for his children.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports stock transactions related to executive compensation. The vesting of performance-based units is a positive signal, but the sale of shares for tax purposes is a neutral event.

Positives

• The vesting of performance-based restricted stock units suggests that Omnicell achieved certain stock performance targets relative to the S&P 1000 Healthcare Index, which could be viewed positively.

Negatives

• The disposal of 18,571 shares to cover taxes, while a normal occurrence, represents a sale of shares by the CEO.

Risks

• Future stock performance may not meet the criteria for further vesting of performance-based restricted stock units.
• Sales of shares by insiders, even for tax purposes, can sometimes be perceived negatively by the market.

Future Outlook

The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period (on each May 15, August 15, November 15, and February 15, respectively).

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership. It provides transparency into the CEO's holdings and the vesting of performance-based equity awards, which are common in the healthcare technology industry to align executive incentives with company performance.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the technology and healthcare sectors.
• Companies like Cerner (now Oracle Health) and McKesson also utilize similar performance-based equity awards to incentivize their executives.
• The specific performance metrics tied to these awards vary, but often include revenue growth, profitability, and total shareholder return relative to a peer group index, such as the S&P 500 or a healthcare-specific index.

Stakeholder Impact

• The vesting of performance-based restricted stock units aligns management's interests with those of shareholders, as it incentivizes executives to achieve stock performance targets.
• The tax-related sale of shares has a minimal impact on stakeholders.

Next Steps

• The remaining performance-based restricted stock units will vest in equal quarterly increments once every three months over a three-year period (on each May 15, August 15, November 15, and February 15, respectively).

Key Dates